EICHORPublic-registry site landscape for NCT05904743, “INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes”, a Diabetes Mellitus, Type 1 study sponsored by Mannkind Corporation. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT05904743 (registry record) |
| Study title | INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes |
| Official title | INHALE-3: A 17-Week Randomized Trial and a 13-Week Extension, Evaluating the Efficacy and Safety of Inhaled Insulin (Afrezza) Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes |
| Sponsor | Mannkind Corporation |
| Condition(s) | Diabetes Mellitus, Type 1 |
| Phase | PHASE4 |
| Listed sites | 19 |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT05904743.
Eichor generates a preliminary site-risk snapshot for NCT05904743 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Diabetes Mellitus, Type 1 trials
More from Mannkind Corporation
← Eichor home · All tracked trials · Diabetes Mellitus, Type 1 studies · Weekly briefs
